Our Scientific Advisory Board

The only responsible way to give out millions of dollars for clinical trial grants is to have a world-class scientific advisory board (SAB).

No items found.

About our Scientific Advisory Board

Our SAB reviews all CETF grant proposals. Chairman Robert Siliciano of Johns Hopkins University hand- picked the advisory board based on their wide range of relevant expertise.

Our board collectively spends approximately 25 work-hours reviewing each credible grant proposal and in the majority of cases, writes a detailed critique that the applicant must sufficiently respond to before funds are authorized. This process is very thorough. For example, one applicant team, spent 96 work-hours preparing a 13-page response (with 24 citations) to the questions posed by our panel.

Our review process is much stricter that of the typical IRB and FDA, which is by design and for everyone’s benefit. We have a limited amount of funds available and want to focus on the most promising research. We also ensure that every trial is well constructed and will yield usable data. While we try to respond to all proposals in five days or less, some grants may take longer due to the level of care put into the review process.

The benefits our board- approved approach are better scientific outcomes, increased patient safety, usable results, full funding in one grant application and fastest time to fund commitment than any other groups funding clinical trials today.

Medical Advisor

Dr. Lisa Danzig, Chief Medical Advisor

Dr. Lisa Danzig is the chief medical advisor of the COVID-19 Early Treatment Fund. Dr. Danzig has spent more than 20 years within the pharmaceutical industry developing vaccines, diagnostics, drugs, and is currently advising companies and investors.

Her experience includes serving as the chief medical officer at PaxVax where she was focused on developing, manufacturing and commercializing specialty vaccines that protect against existing and emerging infectious diseases including Cholera, Typhoid, and chikungunya virus. 


Dr. Danzig spent more than 18 years at Novartis Vaccines and Diagnostics where she worked on the development and licensure of meningococcal vaccines and blood screening solutions, and lived and worked in California, Siena, Italy, Cambridge, MA and Hangzhou, China. She was an EIS officer with the U.S. CDC, where she investigated outbreaks of healthcare-associated infections and taught epidemiology in Côte d’Ivoire to district health officers in West Africa.

Dr. Danzig received her medical degree from Oregon Health Sciences University and completed residency and fellowship training in Internal Medicine and Infectious Diseases in San Francisco. She is currently also an independent director at OrSense and Avisa, director at Payssurance, an advisory committee member at The Lemelson Foundation, serves on the boards of the International Society of Travel Medicine Foundation, the Sustainable Sciences Institute, the Karuna Foundation, acts as an advisor to Kernel, is the co-founder and managing partner at Amicitiam Partners and a member of Pandefense Advisory.

Donate to the
COVID-19 Early Treatment Fund today
Donate